All Articles

NeuroPace will present its RNS System at the Leerink conference, a key moment for the company to showcase its epilepsy treatment to top investors.

Digital accessibility leader AudioEye reports record 2025 earnings and unveils a next-gen platform promising enhanced legal protection for businesses.

Aptiv's board greenlights the spin-off of its electrical systems unit, Versigent, creating two focused companies aimed at distinct automotive futures.

The outdoor gear company reports lower 2025 sales and a net loss but achieves adjusted profit and a debt-free balance sheet on its path to transformation.

OFS Credit's net asset value dropped 20% from market volatility, forcing a dividend cut. Can its strategic moves stabilize the ship for investors?

The Texas Association of Builders has updated its industry-standard contracts. Here’s what they mean for risk, affordability, and homeowner protection.

Major deals with Cadillac and Ferrari mark a pivotal year for Research Frontiers, but can its smart glass tech overcome growing financial losses?

aTyr Pharma heads to a crucial FDA meeting for its lung drug efzofitimod, which missed its main goal but showed significant patient quality-of-life gains.

The data center giant raises major capital to double its capacity, targeting the explosive growth in AI and cloud computing. Here's what it means.

Weebit Nano's advanced memory is at the heart of a South Korean national program aiming to revolutionize AI with ultra-low-power compute-in-memory chips.

As Galapagos pivots its strategy, it brings in a new HR chief to build the high-performing culture crucial for its next chapter of innovation.

Outraged by Canada's enduring water crisis, Quebec high school students are taking their fight for Indigenous rights to the nation's capital.

As CEO Corie Barry prepares for a key UBS conference, investors seek clarity on Best Buy's strategy for growth amid soft sales and a shifting retail landscape.

As Hyperfine preps its 2025 results, investors and clinicians watch to see if its portable Swoop MRI can translate clinical promise into financial success.

NextCure accelerates its high-stakes ovarian cancer drug trial, but with cash dwindling, can it reach the finish line before time runs out?

Inuvo's stock faces uncertainty as a strategic pivot causes a steep Q4 revenue drop, betting its future on its privacy-focused IntentKey AI technology.

The smart baby monitor firm posts a record $105.7M in 2025 revenue and positive adjusted EBITDA, but a significant net loss raises questions.

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

A new CLE series from TruLegal and Today's General Counsel will guide lawyers as AI redefines legal roles, skills, and departmental strategy.

Luminys Systems Corp. unveils its Vertical Experience Center, shifting from generic products to tailored AI security solutions for retail and education.